Jun 2026 (Q2 FY26) — Aug 6, 2026
Immunocore Q2 FY26 — Strong KIMMTRAK Performance and Pipeline Advancement
Read the full callImmunocore (IMCR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Immunocore earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 116 | +18.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -2.6 | +12.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.81 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$29.48 +4.02% · +$1.14
Performance −7.1% 1Y
1Y: $31.72 on 14 Oct 2025 → $29.48. High $40.22 (4 Dec 2025), low $27.79 (8 Jun 2026).
- Previous close
- $28.34
- 52-week range
- $27.79 – $40.22
- One year
- −14.28%
Overview
- Symbol
- IMCR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Immunocore earnings calls (IMCR)
Financials
What the filings say
Net profit, year on year: +92% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 80 | 84 | 94 | 98 | 104 | 104 | 107 | 116 |
| Operating profit | -9 | -19 | -4 | -15 | -7 | -20 | 7 | -3 |
| Operating margin | −10.6% | −23.1% | −3.9% | −15.2% | −6.9% | −18.9% | 6.8% | −2.6% |
| Interest | 4 | 7 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 6 | -25 | 6 | -10 | 0 | -16 | 13 | -1 |
| Tax rate | −43.4% | 4.2% | 17.4% | −6.3% | 158.2% | −90.3% | 2.3% | −57.2% |
| Net profit | 9 | -24 | 5 | -10 | -0 | -30 | 13 | -1 |
| EPS ($ per share) | 0.17 | — | 0.10 | -0.20 | 0 | — | 0.26 | -0.02 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 |
| Reserves | — | -689 | -745 | -796 | -831 |
| Total liabilities | — | 188 | 228 | 649 | 686 |
| Fixed assets | — | 8 | 9 | 10 | 11 |
| Investments | — | — | 0 | 365 | 396 |
| Total assets | — | 527 | 597 | 1,010 | 1,067 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | -143 | -49 | 3 | 26 | -11 |
| Cash from investing | -1 | -2 | -5 | -355 | -16 |
| Cash from financing | 288 | 145 | 34 | 344 | 12 |
| Capital expenditure | -1 | -2 | -5 | -5 | -4 |
| Free cash flow | -144 | -51 | -2 | 21 | -15 |
Insider filings
20 filings between Nov 24, 2025 and Feb 18, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$5.63M
10 sales by 4 insiders
60% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Berman David M | — | $5.21M | Feb 18, 2026 |
| Jallal Bahija | — | $371.2K | Feb 18, 2026 |
| St Leger Tina Amber | — | $32.4K | Feb 18, 2026 |
| GOLL JOHN | — | $22.6K | Feb 18, 2026 |
Latest filings (36)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Feb 18, 2026 | Jallal Bahija CHIEF EXECUTIVE OFFICER | Sale | 11,474 | $371.2K |
| Feb 18, 2026 | GOLL JOHN SVP, FINANCE & CAO | Sale | 698 | $22.6K |
| Feb 18, 2026 | Berman David M HEAD OF R&D | Sale | 5,965 | $193.0K |
| Feb 18, 2026 | St Leger Tina Amber CHIEF HR OFFICER | Sale | 1,000 | $32.4K |
| Feb 17, 2026 | Berman David M HEAD OF R&D | Option exercise | 11,824 | $0 |
| Feb 17, 2026 | Jallal Bahija CHIEF EXECUTIVE OFFICER | Option exercise | 23,817 | $0 |
| Feb 17, 2026 | St Leger Tina Amber CHIEF HR OFFICER | Option exercise | 2,119 | $0 |
| Feb 17, 2026 | GOLL JOHN SVP, FINANCE & CAO | Option exercise | 1,351 | $0 |
| Dec 5, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 572 | $23.0K |
| Dec 5, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 572 | $10.0K |
| Dec 4, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 31,341 | $547.2K |
| Dec 4, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 31,341 | $1.26M |
| Nov 28, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 5,521 | $96.4K |
| Nov 28, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 5,521 | $221.3K |
| Nov 26, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 69,404 | $1.21M |
| Nov 26, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 69,404 | $2.78M |
| Nov 25, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 18,020 | $314.6K |
| Nov 25, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 18,020 | $721.3K |
| Nov 24, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 100 | $1.7K |
| Nov 24, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 100 | $4.0K |
| Sep 30, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 61,849 | $2.18M |
| Sep 30, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 61,849 | $1.08M |
| Sep 15, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 200 | $3.5K |
| Sep 15, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 200 | $7.0K |
| Sep 12, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 1,300 | $47.2K |
| Sep 12, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 21,232 | $756.5K |
| Sep 12, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 22,532 | $393.4K |
| Sep 11, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 19,081 | $692.3K |
| Sep 11, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 19,081 | $333.2K |
| Sep 10, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 30,138 | $1.09M |
| Sep 10, 2025 | Berman David M HEAD OF R&D | Option exercise 10b5-1 plan | 31,338 | $547.2K |
| Sep 10, 2025 | Berman David M HEAD OF R&D | Sale 10b5-1 plan | 1,200 | $44.1K |
| Mar 17, 2025 | BAKER BROS. ADVISORS LP Director | Purchase | 60,110 | $1.79M |
| Mar 17, 2025 | BAKER BROS. ADVISORS LP Director | Purchase | 646,290 | $19.22M |
| Mar 17, 2025 | BAKER BROS. ADVISORS LP Director | Purchase | 8,589 | $253.9K |
| Mar 17, 2025 | BAKER BROS. ADVISORS LP Director | Purchase | 92,349 | $2.73M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Immunocore Holdings plc
Free account. Everything above stays public.
Write why you follow Immunocore Holdings plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading